Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation. (26th May 2019)
- Record Type:
- Journal Article
- Title:
- Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation. (26th May 2019)
- Main Title:
- Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation
- Authors:
- Jin, Haifeng
Jiang, Yang
Du, Fengxia
Guo, Linna
Wang, Guan
Kim, Sang Chan
Lee, Chul Won
Shen, Lei
Zhao, Rongjie - Other Names:
- Olajide Olumayokun A. Academic Editor.
- Abstract:
- Abstract : Pulmonary hypertension (PH) is a progressive and serious disease, where exacerbated inflammatory response plays a critical role. Isoliquiritigenin (ISL), an important flavonoid isolated from Glycyrrhizae radix, exhibits a wide range of pharmacological actions including anti-inflammation. Previously we found ISL alleviated hypoxia-induced PH; in the present study, to extend this, we evaluated the effects of ISL on monocrotaline (MCT)-induced PH and the relevant mechanisms. Rats received a single intraperitoneal injection of MCT, followed by intragastric treatments with ISL (10 mg/kg/d or 30 mg/kg/d) once a day for 28 days. The MCT administration increased the right ventricular systolic pressure (RVSP) ( p < 0.001), the median width of pulmonary arteries ( p < 0.01), and the weight ratio of the right ventricular wall/left ventricular wall plus septum (Fulton index) ( p < 0.01) in rats; however, these changes were inhibited by both doses of ISL ( p < 0.05). In addition, treatment with ISL suppressed the upregulated production of serum interleukin-6 ( p < 0.01) and tumor necrosis factor- α ( p < 0.05) by MCT and reversed the increases in the numbers of proliferating cell nuclear antigen (PCNA)-positive cells ( p < 0.01) in the medial wall of pulmonary arteries. In in vitro experiments, ISL (10 μ M, 30 μ M, and 100 μ M) inhibited excessive proliferation of cultured primary pulmonary artery smooth muscle cells (PASMCs) ( p < 0.05, p < 0.01, and p < 0.001) in aAbstract : Pulmonary hypertension (PH) is a progressive and serious disease, where exacerbated inflammatory response plays a critical role. Isoliquiritigenin (ISL), an important flavonoid isolated from Glycyrrhizae radix, exhibits a wide range of pharmacological actions including anti-inflammation. Previously we found ISL alleviated hypoxia-induced PH; in the present study, to extend this, we evaluated the effects of ISL on monocrotaline (MCT)-induced PH and the relevant mechanisms. Rats received a single intraperitoneal injection of MCT, followed by intragastric treatments with ISL (10 mg/kg/d or 30 mg/kg/d) once a day for 28 days. The MCT administration increased the right ventricular systolic pressure (RVSP) ( p < 0.001), the median width of pulmonary arteries ( p < 0.01), and the weight ratio of the right ventricular wall/left ventricular wall plus septum (Fulton index) ( p < 0.01) in rats; however, these changes were inhibited by both doses of ISL ( p < 0.05). In addition, treatment with ISL suppressed the upregulated production of serum interleukin-6 ( p < 0.01) and tumor necrosis factor- α ( p < 0.05) by MCT and reversed the increases in the numbers of proliferating cell nuclear antigen (PCNA)-positive cells ( p < 0.01) in the medial wall of pulmonary arteries. In in vitro experiments, ISL (10 μ M, 30 μ M, and 100 μ M) inhibited excessive proliferation of cultured primary pulmonary artery smooth muscle cells (PASMCs) ( p < 0.05, p < 0.01, and p < 0.001) in a dose-dependent manner and prevented an increase in the expressions of PCNA ( p < 0.01) and phospho-Akt ( p < 0.05) in PASMCs induced by hypoxia. These results suggest that ISL can attenuate MCT-induced PH via its anti-inflammatory and antiproliferative actions. … (more)
- Is Part Of:
- Evidence-based complementary and alternative medicine. Volume 2019(2019)
- Journal:
- Evidence-based complementary and alternative medicine
- Issue:
- Volume 2019(2019)
- Issue Display:
- Volume 2019, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 2019
- Issue:
- 2019
- Issue Sort Value:
- 2019-2019-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-05-26
- Subjects:
- Alternative medicine -- Periodicals
615.505 - Journal URLs:
- http://ecam.oupjournals.org ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/241/ ↗
http://www.hindawi.com/journals/ecam/ ↗ - DOI:
- 10.1155/2019/4568198 ↗
- Languages:
- English
- ISSNs:
- 1741-427X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3831.036630
British Library HMNTS - ELD Digital store - Ingest File:
- 10814.xml